LYAG CRISPR Activation Plasmid (h): sc-402385-ACT
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- LYAG CRISPR Activation Plasmid (h) is a synergistic activation mediator (SAM) transcription activation system designed to specifically upregulate gene expression
- LYAG CRISPR Activation Plasmid (h) consists of three plasmids at a 1:1:1 mass ratio: a plasmid encoding the deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, and a blasticidin resistance gene; a plasmid encoding the MS2-p65-HSF1 fusion protein, and a hygromycin resistance gene; a plasmid encoding a target-specific 20 nt guide RNA fused to two MS2 RNA aptamers, and a puromycin resistance gene
- The resulting SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by LYAG CRISPR Activation Plasmid (h) and LYAG CRISPR Activation Plasmid (h2) target distinct regulatory regions upstream of the GAA transcriptional start site. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: LYAG Antibody (G-7): sc-373745
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
LYAG CRISPR Activation Plasmid (h) | sc-402385-ACT | 20 µg | $397.00 |
Human GAA encodes lysosomal alpha-glucosidase, a hydrolase required for glycogen catabolism within the endolysosomal system. By converting glycogen to glucose, GAA supports cellular energy homeostasis and prevents lysosomal glycogen accumulation that can disrupt autophagy and broader lysosome-dependent quality control pathways. Reduced GAA activity is linked to lysosomal storage pathology characterized by glycogen buildup and secondary effects on muscle and cardiac cell function. As a result, GAA/LYAG biology is frequently studied in models of lysosomal function, metabolic stress responses, and glycogen handling across diverse cell types.
LYAG CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous GAA expression without altering the underlying DNA sequence.
LYAG CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the GAA locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the GAA transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous LYAG expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native GAA locus and enabling the study of LYAG-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of LYAG pathway restoration in tumor cells with silenced or reduced GAA expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.